Adstiladrin: Uses, Dosage, Side Effects & Warnings - Drugs.com
Dec 9, 2024 · Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer. Includes …
More about ADSTILADRIN® – Bladder Cancer Advocacy Network
What is ADSTILADRIN? ADSTILADRIN (nadofaragene firadenovec-vncg) was approved in the United States in 2022 and is fully available for appropriate patients as a treatment that may help people live …
ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive …
FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus ...
Apr 1, 2025 · Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients …
ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS ...
Adstiladrin (Nadofaragene Firadenovec-Vncg) for bladder cancer
Adstiladrin is also called nadofaragene firadenovec-vncg. Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to bladder cells. …
The Current Treatment Landscape of BCG-unresponsive Non-Muscle …
FDA D.I.S.C.O. Burst Edition: FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Gu√©rin unresponsive non-muscle invasive bladder cancer with …
Anyone treated with Adstiladrin for BCG-unresponsive bladder cancer?
Jul 22, 2024 · As you likely know, Adstiladrin (nadofaragene firadenovec-vncg) was recently approved for bladder cancer. It is a gene therapy currently used for adult patients with high-risk Bacillus …
Nadofaragene Firadenovec for High-risk Non–Muscle Invasive Bladder Cancer
Jan 13, 2023 · The FDA has approved Adstiladrin (nadofaragene firadenovec-vncg) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder …
NMIBC treatment success: Why less frequent dosing and adherence …
Dec 15, 2025 · An example of this treatment advancement is nadofaragene firadenovec-vncg (Adstiladrin),a novel intravesical gene therapy for adults with BCG-unresponsive NMIBC with …